Replies to post #208 on Aptose Biosciences Inc (APTO)

[Wolverine3]

Are you being facetious on the “guaranteed approval”?

[Tartiaboy]

1. "80 mg dose works better than 120 mg and 160 mg." Not sure we have enough data to support that. APTO has most complete picture and chose 120mg as the monotherapy starting dose with flexibility to go up or down. What's important to me at this point is the size of the therapeutic window.

2. Agree!

3. You jest! I am not yet convince about TP53mut. I would like to see at least a couple more. I think NRAS and NPM1 responses are pretty well established.

The data is what it is, encouraging, but not yet convincing.

I consider the montherapy data as an appetizer. I want to see combination data.

[nferna]

Rice was literally Director of the Drug Mechanism Laboratory at NCI.

He may not be the best CEO and everyone is frustrated. We've been through a lot with 253, 806, etc. I get it (I've been in since 2018). But he is not a charlatan. He follows the data (slowly and ploddingly...) On the topic of MOA of tuspetinib, I think it is fair to give him the benefit of the doubt. He has a ton more data, knowledge and experience with this specific topic than anyone on any message board.